Pei-Fung Wu1, Yaw-Sen Chen2, Ting-Yin Kuo1, Hsi-Hsun Lin3, Ching-Wen Liu4, Li-Ching Chang5. 1. Department of Kinesiology, Health and Leisure Studies, National University of Kaohsiung, Kaohsiung, Taiwan, R.O.C. 2. Department of General Surgery, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan, R.O.C. 3. Division of Infectious Diseases, Department of Internal Medicine, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan, R.O.C. 4. School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. 5. Department of Occupational Therapy, I-Shou University, Kaohsiung, Taiwan, R.O.C. Department of Pharmacy, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan, R.O.C. changlc@isu.edu.tw.
Abstract
BACKGROUND: To realize the role of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B (APOBEC3B) in hepatocellular carcinoma (HCC) occurrence, mRNAs of APOBEC3B from tumor and non-tumor tissues of patients with hepatectomy were isolated and in vitro studies were designed. MATERIALS AND METHODS: Seventy-two tumor and non-tumor tissue samples, as well as clinical data, were collected from HCC patients during hepatectomy. The mRNA of APOBEC3B was assessed by real-time polymerase chain reaction. The viability of pLV-APOBEC3B-transfected Hep 3B cells was then determined. Cell growth of pLV-APOBEC3B-transfected Hep 3B cells was evaluated by in vitro migration assay. RESULTS: The real-time polymerase chain reaction results indicated a higher expression of APOBEC3B mRNA in tumor tissues than in non-tumor tissues of patients with HBsAg+ HCC. The expression of APOBEC3B in tumor or non-tumor tissue was not found to be a risk factor of recurrence in patients with HCC. The cell viability assay results indicated the growth-inhibitory effects of APOBEC3B on Hep 3B cells. The cell migration results indicated that APOBEC3B inhibits wound healing in Hep 3B cells. CONCLUSION: Based on these observations, we infer that APOBEC3B is a potential factor contributing to suppression of tumor growth in HCC. Copyright
BACKGROUND: To realize the role of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B (APOBEC3B) in hepatocellular carcinoma (HCC) occurrence, mRNAs of APOBEC3B from tumor and non-tumor tissues of patients with hepatectomy were isolated and in vitro studies were designed. MATERIALS AND METHODS: Seventy-two tumor and non-tumor tissue samples, as well as clinical data, were collected from HCC patients during hepatectomy. The mRNA of APOBEC3B was assessed by real-time polymerase chain reaction. The viability of pLV-APOBEC3B-transfected Hep 3B cells was then determined. Cell growth of pLV-APOBEC3B-transfected Hep 3B cells was evaluated by in vitro migration assay. RESULTS: The real-time polymerase chain reaction results indicated a higher expression of APOBEC3B mRNA in tumor tissues than in non-tumor tissues of patients with HBsAg+ HCC. The expression of APOBEC3B in tumor or non-tumor tissue was not found to be a risk factor of recurrence in patients with HCC. The cell viability assay results indicated the growth-inhibitory effects of APOBEC3B on Hep 3B cells. The cell migration results indicated that APOBEC3B inhibits wound healing in Hep 3B cells. CONCLUSION: Based on these observations, we infer that APOBEC3B is a potential factor contributing to suppression of tumor growth in HCC. Copyright